agp100
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 2, 2026 (NCT07263139)
Timeline
2020s
- Jan 1, 2026
Earliest Phase 2 Sponsor(trial)
Mechanism of action
- Phosphodiesterase 2AINHIBITOR
PDE2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07263139 | Phase 2 | Jan 2, 2026 | Agiana Pharmaceuticals, Viedoc Technologies AB |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agiana Pharmaceuticals | For profit | 1 | 1 | 1 | 2026 |
| Viedoc Technologies AB | For profit | 1 | 0 | 1 | 2026 |
2 organizations
Page 1 / 1